1. Home
  2. BCG vs LSTA Comparison

BCG vs LSTA Comparison

Compare BCG & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BCG

Binah Capital Group Inc.

HOLD

Current Price

$1.69

Market Cap

32.6M

Sector

N/A

ML Signal

HOLD

Logo Lisata Therapeutics Inc.

LSTA

Lisata Therapeutics Inc.

HOLD

Current Price

$3.15

Market Cap

28.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BCG
LSTA
Founded
2016
1980
Country
United States
United States
Employees
150
N/A
Industry
Misc Health and Biotechnology Services
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.6M
28.9M
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
BCG
LSTA
Price
$1.69
$3.15
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$15.00
AVG Volume (30 Days)
80.2K
48.7K
Earning Date
05-14-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
20.42
EPS
N/A
N/A
Revenue
N/A
$35,283,868.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$56.15
N/A
Revenue Growth
N/A
56.90
52 Week Low
$1.36
$1.81
52 Week High
$3.44
$5.07

Technical Indicators

Market Signals
Indicator
BCG
LSTA
Relative Strength Index (RSI) 35.88 37.39
Support Level $1.46 $2.75
Resistance Level $1.90 $3.41
Average True Range (ATR) 0.19 0.14
MACD -0.04 0.05
Stochastic Oscillator 5.62 31.71

Price Performance

Historical Comparison
BCG
LSTA

About BCG Binah Capital Group Inc.

Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.

About LSTA Lisata Therapeutics Inc.

Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.

Share on Social Networks: